Related Experiment Video
Updated: May 30, 2026
Photodynamic Therapy with Blended Conducting Polymer/Fullerene Nanoparticle Photosensitizers
Published on: October 28, 2015
Temoporfin (Foscan®, 5,10,15,20-tetra(m-hydroxyphenyl)chlorin)--a second-generation photosensitizer
Mathias O Senge1, Johan C Brandt
1Medicinal Chemistry, Institute of Molecular Medicine, Trinity Centre for Health Sciences, Trinity College Dublin, St. James's Hospital, Dublin 8, Ireland. sengem@tcd.ie
Abstract:
This review traces the development and study of the second-generation photosensitizer 5,10,15,20-tetra(m-hydroxyphenyl)chlorin through to its acceptance and clinical use in modern photodynamic (cancer) therapy. The literature has been covered up to early 2011.
Insights
This review covers the development and clinical use of the second-generation photosensitizer 5,10,15,20-tetra(m-hydroxyphenyl)chlorin in photodynamic cancer therapy up to 2011.
Area of Science:
- Oncology
- Photochemistry
- Medical Science
Background:
- The evolution of photosensitizers is crucial for advancing photodynamic therapy.
- Second-generation photosensitizers offer improved properties over earlier agents.
Purpose of the Study:
- To review the development and clinical application of 5,10,15,20-tetra(m-hydroxyphenyl)chlorin.
- To document its transition into modern photodynamic cancer therapy.
Main Methods:
- Literature review of scientific publications.
- Analysis of studies on photosensitizer development.
- Examination of clinical trial data up to early 2011.
Main Results:
- The photosensitizer 5,10,15,20-tetra(m-hydroxyphenyl)chlorin has undergone significant development.
- It has achieved acceptance and clinical use in photodynamic therapy.
Conclusions:
- 5,10,15,20-tetra(m-hydroxyphenyl)chlorin is an established second-generation photosensitizer for cancer treatment.
- Its clinical utility in photodynamic therapy is supported by research up to 2011.
